Search This Blog

Saturday, April 13, 2019

Alzheimer’s biotech Cortexyme files for a $86 million IPO

Cortexyme, a Phase 1b biotech developing therapies for Alzheimer’s disease, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol CRTX. Cortexyme filed confidentially on March 4, 2019. BofA Merrill Lynch and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.

Inappropriate pain management after surgery seen as big cause of opioid crisis

Targets to eliminate pain after surgery have driven increases in the use of opioids, and are a major cause of the opioid crisis in the USA, Canada and other countries. For the first time, a new Series of three papers, published in The Lancet, brings together global evidence detailing the role of surgery in the opioids crisis.
Chronic post-surgical  is a growing problem as the population ages and more surgeries are done. It can occur after any type of surgery. Each year there are 320 million people having surgery, and chronic pain occurs in 10% of cases.
It typically begins as acute postoperative pain that is difficult to control, and develops into a persistent pain condition with features that are unresponsive to opioids. In response to this pain, clinicians often prescribe higher levels of opioids, but this can lead to tolerance and opioid-induced hyperalgesia (a counterintuitive increase in pain in line with increased opioid consumption), creating a cycle of increased pain and increased  where pain remains poorly managed.
“Providing opioids for surgical patients presents a particularly challenging problem requiring clinicians to balance managing acute pain, and minimising the risks of persistent opioid use after surgery,” says Series lead Professor Paul Myles, Monash University, Australia. “Over the past decade there has been an increasing reliance on strong opioids to treat acute and chronic pain, which has been associated with a rising epidemic of prescription opioid misuse, abuse, and overdose-related deaths. To reduce the increased risk of opioid misuse for , we call for a comprehensive approach to reduce opioid prescriptions, increase use of alternative medications, reduce leftover opioids in the home, and educate patients and clinicians about the risks and benefits of opioids.”
Risks associated with prescription opioids
The opioid crisis began in the US during the mid-1990s and early 2000s, when inadequate pain relief was seen as a marker of poor quality healthcare. Opioids are now one of the most commonly prescribed medications in the USA with similar, although less marked, trends in other high-income countries, including the UK. Comparatively, many low-income countries worldwide have little access to opioids and cannot provide appropriate pain relief—as highlighted in The Lancet Commission on Global Access to Palliative Care and Pain Relief.
“From the mid-1990s, clinical guidelines and policies were created that aimed to eliminate pain, and clinicians were encouraged to increase opioid prescriptions. As a result, the use of prescription opioids more than doubled between 2001-2013 worldwide—from 3 billion to 7.3 billion daily doses per year, and has been linked to increases in misuse and abuse in some countries—like the US, Canada, Australia and the UK.” Says Series author Dr. Brian Bateman, Brigham and Women’s Hospital, USA.
Currently, opioids are often the best pain relief available for managing acute pain. In surgery, opioid administration reduces the dose of general anaesthetic needed, and timely and appropriate opioids after surgery improve patient comfort. However, the persistent use of opioids after surgery can predispose patients to long-term opioid use and misuse so ongoing must be carefully considered. In the USA, opioid prescribing for minor surgery has increased (up to 75% of patients are prescribed opioids at hospital discharge), and the risk of misuse increases by 44% for every week and for repeat prescription after discharge.
A US study of more than 155,000 patients having one of four low-risk surgeries (carpal tunnel repair, knee arthroscopy, keyhole surgery for gallbladder removal, or keyhole surgery for inguinal hernia repair) found that opioid prescriptions for each increased from 2004-2012, and that the average daily dose of opioid prescribed for post-surgical pain also increased by 13% (30 milligrams of morphine equivalent [MME]) across all procedures on average, with increases ranging from 8% (17 MMEs) for patients undergoing inguinal hernia repair to 18% (45 MMEs) for patients undergoing knee arthroscopy (see Figure in paper 2).
There are also marked international differences in opioid prescribing after surgery. Data comparing one US and one Dutch hospital found that 77% of patients undergoing hip fracture repair in the US hospital received opioids, whereas none did in the Netherlands hospital, and 82% of US patients received opioids after ankle fracture repair compared with 6% of Dutch patients. Despite these differences, patients in each of these countries show similar levels of satisfaction with pain management.
In addition, excessive amounts of opioids are prescribed to US patients after surgery. Studies between 2011-2017 found that 67-92% of US surgery patients reported not using all of their opioid tablets, typically leaving 42-71% of their prescribed pills unused.
As well as often being ineffective at treating chronic pain, opioid prescriptions for pain after surgery have been linked to prescription opioid misuse and diversion, the development of opioid use disorder, and opioid overdose. Storing excess opioid pills in the home is an important source of diversion, and in one study 61% of surgery patients had surplus medication with 91% keeping leftover pills at home.
Reducing opioid risks and improving management of chronic post-surgical pain
The authors call for a comprehensive approach to reduce these risks, including specialist transitional pain clinics, opioid disposal options for patients (such as secure medication disposal boxes and drug take-back events) to help reduce home-stored opioids and the risk of diversion, and options for non-opioid and opioid-sparing pain relief. More research is also needed to help effectively manage opioid tolerance and opioid-induced hyperalgesia.
“Ultimately, chronic pain after surgery requires a comprehensive biopsychosocial approach to treatment. Transitional pain clinics are a new approach at bridging the divide, aiming to eliminate overprescribing of opioids after surgery. These clinics could help identify those at risk of chronic pain after surgery, and offer additional clinic visits, review treatment, refer the patient to alternative services, such as rehabilitation, addiction medicine, mental health services, and chronic pain services. Together this could help to reduce opioid use and abuse.” says Professor Myles.
Clinical guidelines and policies must also provide consensus for prescribing opioids after surgery, offering clinicians default and maximum prescription levels. For example, there is currently no guide on how long  should remain on opioids. To counter this, in the USA, a study devised prescribing recommendations for various surgeries (based on patient surveys and prescription refills data) – recommending postoperative opioids for 4-9 days for general surgery procedures, 4-13 days for women’s health procedures, and 6-15 days for musculoskeletal procedures. In addition, a study that adapted the default number of opioid pills prescribed from 30 to 12 showed marked decreases in the number of pills given after 10 common surgical procedures.
“Better understanding of the effects of opioids at neurobiological, clinical, and societal levels is required to improve future patient care,” says Series author Professor Lesley Colvin, University of Dundee, UK. “There are research gaps that must be addressed to improve the current opioid situation. Firstly, we must better understand opioid tolerance and opioid-induced hyperalgesia to develop pain relief treatments that work in these conditions. We also need large population-based studies to help better understand the link between opioid use during surgery and , and we need to understand what predisposes some people to opioid misuse so that we can provide alternative pain relief during  for these . These recommendations affect many areas of the  crisis and could benefit to the wider crisis too.”

Explore further

More information: The Lancet (2019). www.thelancet.com/series/Posto … nagement-and-opioids

Controversial China experiment adds human brain-linked gene to ape genome

A team of researchers working in China has created several transgenic rhesus monkeys by adding a human gene involved in brain growth to the monkey’s genome. In their paper published in the National Science Review, the group describes their work and the testing they conducted on the monkeys after they were born.
Bioscientists are making moves to start using gene editing techniques on humans, both to prevent diseases and to learn more about how . In this new effort, the team in China has added a human gene called MCPH1 to the genome of several rhesus  as a means of learning more about human development. Prior research has shown that MCPH1 is involved in the growth of the brain—babies born without it have small brains.
To get the gene into the monkey genomes, the researchers simply injected viruses carrying the gene into monkey embryos and then allowed the monkeys to develop naturally. Eleven monkeys with the modified genome were born, but only five survived. Those five were tested to see what impact the human gene had on their development and abilities.
The researchers report that none of the monkeys had larger than normal brains, but all of them tested better than average on  and in processing abilities.
The research, which was conducted by a team in China, is quite controversial—it would not have been allowed in most other countries. There’s a consensus in the bioscience community that adding  related to brain development to monkey genomes crosses an ethical line. Some believe it could lead to monkeys like those seen in the movie Planet of the Apes. What sort of status would such monkeys have if they were altered in ways that allowed them to think like a human being? For this reason, most are not willing to take part in such research—indeed, even one of the researchers on the team in China, an American from North Carolina University, had second thoughts. He suggested that creating monkeys that have some aspects of human brain power “is not a good direction.” He claims he only assisted with MRI analysis for brain volume testing.

Explore further

More information: Lei Shi et al. Transgenic rhesus monkeys carrying the human MCPH1 gene copies show human-like neoteny of brain development, National Science Review (2019). DOI: 10.1093/nsr/nwz043

Sanders officially revives Medicare-for-all, but Plan B for Dems gains traction

Many presidential hopefuls, even official co-sponsors of Sanders’ Medicare-for-All proposal, are at the same time edging toward a more incremental approach, called ‘Medicare for America.’


As Democratic presidential primary candidates try to walk a political tightrope between the party’s progressive and center-left wings, they face increasing pressure to outline the details of their health reform proposals.
On Wednesday, Sen. Bernie Sanders (I-Vt.) reaffirmed his stance by reintroducing a “Medicare-for-all” bill, the idea that fueled his 2016 presidential run.
As with its previous iterations, Sanders’ latest bill would establish a national single-payer “Medicare” system with vastly expanded benefits, prohibit private plans from competing with Medicare and eliminate cost sharing. New in this version is a universal provision for long-term care in home and community settings (but Medicaid would continue to cover institutional care).
Already, it has an impressive list of Senate cosponsors — including Sanders’ rivals for the Democratic presidential nomination, Cory Booker (D-N.J.), Kirsten Gillibrand (D-N.Y.), Kamala Harris (D-Calif.) and Elizabeth Warren (D-Mass.).
But many of the candidates — even official Medicare-for-all co-sponsors — are at the same time edging toward a more incremental approach, called “Medicare for America.” Proponents argue it could deliver better health care to Americans while avoiding political, budgetary and legal objections.
It comes as politicians tread carefully over the political land mines a Medicare-for-all endorsement could unleash, while seeking to capitalize on a growing appetite for health reform.
During the 2018 midterm election campaigns, some congressional candidates talked about allowing people older than 55 to join Medicare, or allowing people younger than 65 to buy into it if they choose (the “public option”). Many aren’t eager to face the industry opposition that a full-on Medicare expansion would surely trigger.
From the consumer perspective, sweeping reform poses a risk. Despite Medicare’s popularity with its beneficiaries, the majority of Americans express satisfaction with their health care, and many are nervous about giving up private options. Also, many analysts are worried that a generous Medicare-for-all plan that promises everything would break the bank without any patient payments.
That tension is pushing a number of candidates toward an emerging option called “Medicare for America.” The bill was introduced last December to little fanfare by two Democrats, Rep. Rosa DeLauro (Conn.) and Rep. Jan Schakowsky (Ill.). It hasn’t been reintroduced in the new Congress.
This proposed system would guarantee universal coverage, but leaves job-based insurance available for those who want it. Unlike Medicare-for-all, though, it preserves premiums and deductibles, so beneficiaries would still have to pay some costs out-of-pocket. It allows private insurers to operate Medicare plans as well, a system called Medicare Advantage that covers about a third of the program’s beneficiaries currently, and which would be outlawed under Medicare-for-all.
“Before policies get defined, what you see is people endorsing a plan that is a little, perhaps, less subject to early attack,” said Celinda Lake, a Democratic pollster. “A lot of candidates feel if they endorse a plan that leaves some private insurance, they get more time to say what their ideas are about.”
Medicare for America got its first high-profile endorsement from former Texas Rep. Beto O’Rourke, who launched his own 2020 bid in mid-March. Other candidates — including Warren, Gillibrand and Pete Buttigieg, the mayor of South Bend, Ind. — have tiptoed toward it without making any endorsements, suggesting they back Medicare-for-all in theory but also support a system that retains private insurance, at least temporarily.
Such an approach is perhaps unsurprising. Polling indicates voters want strong health reform. Candidates, election experts say, need something powerful to deliver.

Improving the Affordable Care Act, an idea backed by Sen. Amy Klobuchar, a Minnesota Democrat running in the primary’s moderate lane, may not suffice.
“The ACA is popular at the 50 percent level, but it’s not energetic. It doesn’t get people who really like it,” Blendon said. “What they’re looking for is something that is exciting but isn’t threatening.”
Both Medicare-for-all and Medicare for America, experts noted, offer something that presidential candidates can campaign on and a health alternative that at first blush sounds appealing to many. But the latter could skirt some potential obstacles.
Approval for Medicare-for-all drops when people learn that, under such a program, they would likely lose their current health plan (even if the government-offered plan could theoretically provide more generous coverage).
The cost-sharing element of Medicare for America, meanwhile, would ostensibly quiet some of the concerns about paying for Medicare’s expansion, though critics on the left worry it would mean some people would still be unable to afford care.
This also tracks with recent polling which suggests that, while Medicare-for-all support can be swayed, voters of all political stripes favor some sort of way to extend optional Medicare coverage, without necessarily eliminating the private industry altogether.
Employers would have to offer plans that were at least as generous as the government program, or direct employees to Medicare. Employers who stop offering health benefits would have to pay a Medicare payroll tax.
For now, most candidates are still avoiding a concrete stance on Medicare for America. Despite signs of interest, the Buttigieg, Gillibrand and Warren campaigns all declined to directly answer questions about whether they endorse Medicare for America. The campaigns of other candidates in the race — Harris, Klobuchar, Booker, former Housing and Urban Development Secretary Julian Castro and Washington Gov. Jay Inslee — similarly declined to comment.
Reading between the lines, though, their promises to achieve universal health care by expanding Medicare — while retaining private insurance — leaves them few options besides something like Medicare for America, argued one of its main architects.
“There are variations besides this particular plan, but once you start to actually dig into this, if you want universal coverage you’re going to have to do the kinds of things” spelled out in Medicare for America, argued Jacob Hacker, a political scientist at Yale University, who played a lead role in devising this proposal.
Still, though, it has prompted objections from both the left and the right.
On the far left, the cost sharing is a dominant concern. (Under Medicare for America, an individual would have a $3,500 out-of-pocket limit; a family would have a $5,000 limit. Premiums would be capped at almost 10% of a household’s income.) Those critics also say the plan’s accommodations to private insurance limit the government’s ability to negotiate lower prices.
Conservatives repeat many of the arguments levied against Medicare-for-all — too expensive, too disruptive.
Hospitals, insurance, drugmakers and doctors, who have already mobilized against Medicare-for-all, also can be expected to make just as strong a showing against Medicare for America, political analysts said. More Medicare means less revenue for the medical industry.
Said David Blumenthal of the Commonwealth Fund: “The fact of expanded Medicare will be the focus of attacks.”

Health-insurance industry working to pull Dems away from Medicare-for-all

At a company town hall meeting in late February, a UnitedHealthcare executive assured employees that the private health insurance giant was indeed working to undercut support for Democratic lawmakers’ push for Medicare-for-all. But the company, he said, is trying to tread lightly.
“One of the things you said: ‘We’re really quiet’ or ‘It seems like we’re quiet.’ Um, we’ve done a lot more than you would think,” chief executive Steve Nelson said in response to an employee’s question about the company’s role in the Medicare-for-all debate, according to a video of his remarks obtained by The Washington Post. “You want to be kind of thoughtful about how you show up and have these kind of conversations, because the last thing you want to do is become the poster child during the presidential campaign.”
The remarks come amid a broader push from the health insurance industry to prevent legislation to enact Medicare-for-all from getting off the ground, including by trying to direct Democrats toward more centrist efforts and reject plans that would effectively legislate many of the companies out of existence.
Wary of bringing unwanted political controversy to their companies, some private health-care firms have in part relied on advocacy groups and lobbyists in their fight against Medicare-for-all — joining the push without leaving too many company-specific fingerprints.
Congressional Democrats, including some of the party’s leading 2020 presidential contenders, are pushing proposals that would establish a single-payer health-care system in which all Americans would receive government insurance. Legislation in both the House and the Senate would outlaw coverage that is duplicative with generous government plans, reducing the multibillion-dollar health insurance industry to a small, supplemental role.
The bills are still long-shot proposals that are near-universally opposed by Republicans, and their passage into law would require Democrats to take the White House in 2020 and win sizable majorities in both chambers of Congress. But they have moved from a fringe position among Democratic lawmakers to a goal that is broadly embraced by much of the party.
Facing this threat, some private health companies are mounting a lobbying offensive, sending literature to staff members on Capitol Hill, starting advertising campaigns, and regularly warning politicians, reporters and the public about the dangers of a single-payer system.
These private insurers have pushed for Democrats to instead focus on repairing the Affordable Care Act passed under President Barack Obama, arguing a more incremental approach could include extending health insurance to all Americans without requiring a radical transformation of existing markets.
“These companies completely understand that the federal government can discipline prices, and that doing so could have a fundamental impact on every single thing in their business,” said Harold Pollack, a health-care expert at the University of Chicago, referring to proposals that could set prices or create government programs to compete with private insurers.
In an email, UnitedHealth spokesman Tyler Mason said Nelson’s comments came during an internal company meeting and were made in response to a question from an employee who may not have known about the company’s existing policy positions, which have been publicly available for many years. Mason pointed to a company report that calls for, among other policies, expanding Medicaid and protecting the health insurance that tens of millions of Americans receive through their employers.
“We have publicly supported universal coverage for over 20 years and have been engaging in thoughtful conversations with policymakers, employers, care providers and our own employees on solutions that build upon the success of existing public-private partnerships,” Mason said in an email.
In the February meeting with employees, Nelson said the company opposes Medicare-for-all because it excludes the private sector, which he said does a better job of delivering health care than the government, and said he doubted how a single-payer system could be funded or effectively administered.
“We are advocating heavily and very involved in the conversation,” Nelson said. “Part of it is trying to be thoughtful about how we enter in the conversation, because there’s a risk of seeming like it’s self-serving.”
The UnitedHealth Group, which recorded about $17 billion in earnings in 2018, spent about $8 million on lobbying efforts last year on a broad range of health-care issues, according to the Center for Responsive Politics, which tracks money in politics. The company, the parent of UnitedHealthcare, declined to comment on whether it had met with Democratic presidential candidates.
Other industry groups also are fighting back against a single-payer system. America’s Health Insurance Plans, a trade association representing private health insurers, has lobbied Congress on a single-payer bill by Sen. Bernie Sanders (I-Vt.), as has the Healthcare Leadership Council, an industry group whose members include private health insurance giants such as Anthem, according to the Center for Responsive Politics.
AHIP last summer also joined with insurers such as Blue Cross Blue Shield, as well as hospital associations and pharmaceutical companies, in forming a group called the Partnership for America’s Health Care. In February, the partnership — whose members spent $143 million on lobbying in 2018 — said it would begin a six-figure digital advertising campaign to oppose both Medicare-for-all and a public option that would allow Americans to buy into Medicare. The group also is running an ad attacking Rep. Lori Trahan (D-Mass.) for backing Medicare-for-all legislation, according to Politico.
A report in Splinter, a left-leaning publication, revealed last month that several people quoted in the partnership’s news releases had ties to lobbying firms or private health insurance companies not mentioned in the statements. A spokesman for the group declined to comment on the Splinter story, but Lauren Crawford Shaver, executive director of the partnership, said the organization is committed to “fixing what is broken so that it works better for every American,” such as by improving the number of Americans with insurance and reducing health-care costs for consumers.
On Capitol Hill, meanwhile, about half a dozen representatives of lobbying firms said they had pushed for meetings with Democrats over single-payer and other proposed government expansions of health care. Lobbyists with the National Association of Health Underwriters, which represents health insurance agents and brokers, recently delivered a list of talking points critical of Medicare-for-all to Sen. Jacky Rosen (D-Nev.). It included the argument that single-payer “would be prohibitively expensive” and “reduce the standards of quality and access Americans currently enjoy in their health care.”
“You have a new majority with a lot of new members, so it’s a whole new pool of folks to get in and talk to,” said Robert G. Siggins, a senior policy adviser at the lobbying firm Alston & Bird who previously served as the chief of staff to a House Democrat. Siggins has lobbied on behalf of several private health-care companies. “You’re really trying to get a sense of where they’re coming from, and provide information.”
Democratic staff members also are receiving mailers warning against health plans that fall short of single-payer health care. One report sent last month to Senate Democratic offices, written by the KNG Health Consulting group but prepared on behalf of the American Hospital Association and Federation of American Hospitals, warned against “Medicare X,” a plan from moderate Democratic Sens. Michael F. Bennet (Colo.) and Tim Kaine (Va.) that would allow all Americans to buy into a public health insurance plan, according to a copy of the report.
To some political insiders, this lobbying push from private health-care companies underscores the enormous obstacles facing Medicare-for-all legislation and other large government interventions in health care. When Obama pushed the Affordable Care Act, Democrats tried working with private insurers and hospitals to minimize industry opposition to the legislation. Health insurance companies at the time helped defeat a proposed “public option” that would have competed with private plans.
“The insurance industry is still a very powerful force within the political process,” said Jim Manley, who served as an aide to former Senate majority leader Harry M. Reid (D-Nev.). “Having them on the opposite side of single-payer will be a very difficult obstacle to overcome.”
But single-payer advocates have argued for the necessity of their more radical proposal to transform the American health system, noting that the United States spends about twice as much per person as peer nations on health care despite lagging behind significantly on several key health indexes. To supporters of single-payer, the frenzy of federal lobbying against Medicare-for-all highlights the need to upend the health-care status quo.
“When the people begin organizing against private insurance, the lonely insurance executives turn to their only friends: the elected officials beholden to their cash,” said Tim Faust, an activist for single-payer health care.

Top Hospital Lobbyist Predicts Pelosi Will Block Vote on Medicare for All

A top hospital lobbyist told a room of health care executives this week not to worry about “Medicare for All” and suggested that House Speaker Nancy Pelosi (D-Calif.) won’t let the idea come up for a vote during the current Congress.
Tom Nickels, the American Hospital Association’s (AHA) executive vice president for government relations, spoke at the organization’s annual conference on Monday, a day before Pelosi addressed the same Washington, D.C. ballroom.
Although Nickels said that President Donald Trump and the Republican-controlled Senate would never support the idea of a government-run universal health care system, he predicted Pelosi also will work to block Medicare for All legislation, in hopes of protecting moderate Democrats in swing districts.
“We’re going to hear again from Mrs. Pelosi tomorrow,” he said. “She’s trying to thread the needle here, and she understands the difficulty that Medicare for All will provide for her caucus and for some of her members who have to go get re-elected, and my guess is she’s going to be pretty adept in making sure that nothing comes up that harms her members.”
Indeed, Pelosi—who, along with the Democratic House leadership and party committee, has received hundreds of thousands of dollars from anti-Medicare for All interests—did try to thread the needle at AHA’s conference on Tuesday. “We all share a common goal: quality, affordable health care coverage for all,” she said. “There are many paths to this goal; you’ve heard of some of them. Some of them may not be advocated today. Medicare for all, single payer, whatever it is, all that creative tension is valuable as we go forward.”
“But we can’t go down any path unless you strengthen the Affordable Care Act,” she said, referring to the 2010 health care law that Republicans have sought to overturn and have chipped away at for almost a decade. Although the ACA forced insurers to cover patients with pre-existing health conditions, nearly 14 percent of American adults were still uninsured at the end of 2018, according to Gallup. Insurance premiums, deductibles, and copays have continued to increase. The U.S. spends roughly twice what other high-income countries do on health care—with worse results.
While Medicare for All is popular among voters, the party’s presidential candidates, and 108 House Democrats, Pelosi and other House leaders have questioned the potential costs of such a program and whether Americans would want to abandon their private health insurance plans. Congress will hold hearings on Medicare for All, but Pelosi hasn’t promised a floor vote for any single-payer bills.
“For a century, powerful corporations have been the main obstacle blocking the achievement of real universal healthcare in this country,” Adam Gaffney, president of Physicians for a National Health Program, told Sludge and MapLight. “Improved Medicare for All is popular and achievable—we know how it would work, how to set it up, how to run it. The problem is the deep-pocketed interests who are happy with the status quo, who have limitless money to burn to keep the gravy train running.”

Bankrolling Democratic Leaders

The AHA is one of more than two dozen health care trade organizations and companies that are members of the Partnership for America’s Health Care Future (PAHCF), a coalition created last year to oppose Medicare for All. A PAHCF spokesperson told MapLight and Sludge that it is a 501(c)(4) social welfare nonprofit organization registered in Delaware.
Since 2009, Pelosi has received $243,000 in campaign donations from PAHCF members’ employees, and their corporate political action committees, including $55,000 from the AHA, according to an analysis of Federal Election Commission data by MapLight and Sludge. Pelosi’s top deputy, House Majority Leader Steny Hoyer (D-Md.) has received $360,000 from PAHCF members, including $50,000 from AHA, $55,000 from the Federation of American Hospitals,  and $50,000 from the American Medical Association.
Last week, Sludge and MapLight reported that corporate lobbyists with clients in the health care industry, including PAHCF members, raised $440,000 during the first two months of the year for the Democrats’ main House elections arm, the Democratic Congressional Campaign Committee (DCCC). Politico reportedthis week that a number of House Democrats who have pledged to reject corporate PAC donations have held fundraisers with corporate lobbying firms or accepted donations from their employees.
PAHCF members’ PACs have contributed more than $1.2 million to the DCCC since 2009, including more than $190,000 from the AHA. The Council of Insurance Agents & Brokers has donated $152,000 to the DCCC, and has also given $90,000 to the committee’s “building fund.” PAHCF members and their employees have also donated $76,000 to the campaigns of DCCC chairwoman Cheri Bustos (D-Ill.) since she first started running for Congress in 2011. Bustos has received $34,000 from the AHA.
“The AHA and the other members of the PAHCF are clearly under the impression that if they spend enough, Democratic leadership will undercut Medicare for All,” said Dylan Dusseault, executive director of the Business Initiative for Health Policy, an advocacy group that supports Medicare for All. “So far, they’ve been proven right.”
“Instead of championing an issue that is incredibly popular with their voters, leadership has tried to divert attention towards tweaking a system that is fundamentally broken,” Dusseault said. “They need to demonstrate they care more about the American patients, families, workers, and businesses who are drowning in our healthcare system than the interests of a handful of donors.”
Although the DCCC recently prohibited its political consultants and vendors from working with Democratic candidates who decide to challenge the party’s incumbents, it has said nothing about PAHCF’s recent online advertising campaign attacking incumbent Rep. Lori Trahan (D-Mass.) a Medicare for All supporter.
A positive Facebook ad from PAHCF features Bustos and a quote attributed to her about the need to fix the Affordable Care Act.
Another PAHCF ad, which ran on Facebook and Twitter, highlighted some of Pelosi’s criticisms of Medicare for All, noting that she’s asked, “How’s it gonna be paid for?”
View image on Twitter
Partnership for America’s Health Care Future@P4AHCF
As we mark the ninth anniversary of the ACA – we want to know: “Will Democratic Leaders Defend ACA, Or Support ‘Scary’ Medicare For All, Which Eliminates It?” Dig in here → https://americashealthcarefuture.org/what-they-are-saying-americans-urge-elected-officials-to-protect-what-is-working-reject-one-size-fits-all-health-care-2/ 
“Together, we will not relent in our shared mission to end injustice in health and advance progress for all,” Pelosi said at the end of her Tuesday speech. “Thank you all for your leadership on this important issue, and thank you for the honor of meeting with you today.”
Through a huge round of applause, Pelosi then read aloud the AHA’s slogan for the conference: “Meeting today’s challenges, creating a healthier tomorrow,” she said. “That’s a good mission for all of us.”

One-two punch helps solve greatest unmet need in cardiology

Nearly half of current hospital admissions for heart failure are caused by a type of the disease with no treatment options. Cardiology researchers at UT Southwestern Medical Center are changing that reality with a fresh approach, recently published in Nature.
“There are two types of heart failure. One is called HFrEF, for which we have a number of therapies, including medications, devices, and transplants. The other — HFpEF — has zero options,” explained UT Southwestern Chief of the Division of Cardiology and Professor of Internal Medicine and Molecular Biology Dr. Joseph Hill.
“HFpEF is the single greatest unmet need in cardiology. Finding a new way to examine it represents a significant advance, as it provides a model necessary to develop and test therapies that could save lives worldwide,” said Dr. Hill, who holds the James T. Willerson, M.D. Distinguished Chair in Cardiovascular Diseases and the Frank M. Ryburn, Jr. Chair in Heart Research.
The Centers for Disease Control and Prevention estimates that 5.7 million people have heart failure in the U.S.
Heart failure with preserved ejection fraction (HFpEF) is a lethal disorder for which there are no effective clinical therapies. The heart muscle becomes too stiff to pump blood efficiently. Most HFpEF patients are obese, have diabetes, and have metabolic syndrome.
Heart failure with reduced ejection fraction (HFrEF) functions differently. In HFrEF, also known as systolic HF, the heart muscle is not able to contract adequately and, therefore, expels less oxygen-rich blood into the body. Previous heart failure models of HFpEF focused on raising the levels of an enzyme called NO, or nitric oxide synthase.
However, in HFpEF, there is actually too much of the NO enzyme. A strike on this target — with a medical inhibitor, for example — would solve the problem. According to Dr. Hill, there are already FDA-approved drugs that inhibit this NO-synthesize enzyme, which could facilitate developing new treatments rapidly.
The two-hit model
Dr. Hill’s team looked at current, ineffective models of HFpEF and concluded that none of them correctly mirrors the realities they see clinically in human patients. They found that combining a high-fat diet with a drug that raises blood pressure gave them a “two-hit” model, like a one-two punch to the disease.
Next, the team examined results of their model at the cellular level and compared them with human cells. They found that they had replicated the human condition, thereby providing scientists an accurate biological picture that can greatly advance the development of new treatments.
“A recognized research gap in the HFpEF field is the lack of relevant experimental models that adequately represent the progression of this complex disorder. This study is an example of how advances in HFpEF models can lead to a better understanding of the disease pathophysiology and new ideas for therapeutic strategies,” said Dr. Bishow Adhikari, a program officer for the study and a scientist with the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, which helped fund the study.
Millions of people worldwide have both obesity and diabetes. The research team believed that these two conditions would lead to HFpEF — a hypothesis they confirmed by duplicating the disease conditions and examining changes at the molecular level.
“Heart failure is one of only two forms of cardiovascular disease that is increasing. It’s exploding around the world,” Dr. Hill said. “We dance around the edges of it, treating patients’ diabetes, blood pressure, and other conditions. With this model, we’ll be able to get to the underlying cause so we can get to the root of the problem.”
The UT Southwestern researchers are currently taking steps toward moving into human clinical trials based on findings in their preclinical two-hit model. With time, they expect that all heart failure patients will have treatment options.
Story Source:
Materials provided by UT Southwestern Medical CenterNote: Content may be edited for style and length.

Journal Reference:
  1. Gabriele G. Schiattarella, Francisco Altamirano, Dan Tong, Kristin M. French, Elisa Villalobos, Soo Young Kim, Xiang Luo, Nan Jiang, Herman I. May, Zhao V. Wang, Theodore M. Hill, Pradeep P. A. Mammen, Jian Huang, Dong I. Lee, Virginia S. Hahn, Kavita Sharma, David A. Kass, Sergio Lavandero, Thomas G. Gillette, Joseph A. Hill. Nitrosative stress drives heart failure with preserved ejection fractionNature, 2019; DOI: 10.1038/s41586-019-1100-z